Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension
Status:
COMPLETED
Trial end date:
2023-01-27
Target enrollment:
Participant gender:
Summary
This study purpose is to determine the appropriate combination drug dose by comparing safety and efficacy with placebo, candesartan, and amlodipine monotherapy after 8 weeks of administration of SPC1001 to patients with essential hypertension.